首页> 美国卫生研究院文献>PLoS Clinical Trials >Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection
【2h】

Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection

机译:改进的BM212 MmpL3抑制剂类似物在急性肺部感染的小鼠模型中显示功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1,5-Diphenyl pyrroles were previously identified as a class of compounds endowed with high in vitro efficacy against M. tuberculosis. To improve the physical chemical properties and drug-like parameters of this class of compounds, a medicinal chemistry effort was undertaken. By selecting the optimal substitution patterns for the phenyl rings at N1 and C5 and by replacing the thiomorpholine moiety with a morpholine one, a new series of compounds was produced. The replacement of the sulfur with oxygen gave compounds with lower lipophilicity and improved in vitro microsomal stability. Moreover, since the parent compound of this family has been shown to target MmpL3, mycobacterial mutants resistant to two compounds have been isolated and characterized by sequencing the mmpL3 gene; all the mutants showed point mutations in this gene. The best compound identified to date was progressed to dose-response studies in an acute murine TB infection model. The resulting ED99 of 49 mg/Kg is within the range of commonly employed tuberculosis drugs, demonstrating the potential of this chemical series. The in vitro and in vivo target validation evidence presented here adds further weight to MmpL3 as a druggable target of interest for anti-tubercular drug discovery.
机译:1,5-二苯基吡咯以前被鉴定为一类对结核分枝杆菌具有高体外功效的化合物。为了改善这类化合物的物理化学性质和类药物参数,进行了药物化学研究。通过为N1和C5处的苯环选择最佳的取代方式,并用吗啉取代一个硫代吗啉部分,制备了一系列新的化合物。用氧代替硫得到的化合物具有较低的亲脂性并改善了体外微粒体的稳定性。此外,由于该家族的亲本化合物已显示出靶向MmpL3的作用,因此已分离出对两种化合物有抗性的分枝杆菌突变体,并通过对mmpL3基因进行测序来表征。所有的突变体都显示出该基因的点突变。迄今为止确定的最佳化合物已在急性鼠结核病感染模型中进行了剂量反应研究。产生的49 mg / Kg ED99在常用的结核病药物范围内,证明了该化学系列的潜力。此处提供的体外和体内靶标验证证据进一步增加了MmpL3的重量,作为抗结核药物发现的可关注药物靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号